Alpha-lipoic acid (ALA) is a sulfur-containing antioxidant naturally produced in the body that assists in energy metabolism and can regenerate other antioxidants including vitamins C and E, glutathione, and CoQ10. It has been most extensively studied for diabetic peripheral neuropathy, blood sugar control, and weight loss. The R-isomer is the biologically active form, though most supplements contain a 50/50 racemic mixture. Evidence supports modest benefits for some conditions, but clinical relevance is debated and gastrointestinal side effects are common at higher doses.
Table of Contents
- Overview
- Forms and Bioavailability
- Evidence for Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- References
Overview
Alpha-lipoic acid (ALA), also known as lipoic acid or thioctic acid, is a sulfur-containing compound naturally produced in the body. It functions as a cofactor for mitochondrial enzymes — specifically pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — that are essential for converting glucose into cellular energy (ATP) [1][2]. Unlike most antioxidants, alpha-lipoic acid is both water-soluble and fat-soluble, meaning it can function in virtually every tissue and cellular compartment in the body [1][2].
Alpha-lipoic acid has a unique dual role. First, it is a potent direct antioxidant capable of neutralizing free radicals including reactive oxygen species (ROS) and reactive nitrogen species. Second, it is capable of regenerating other antioxidants — including vitamins C and E, glutathione, and coenzyme Q10 — after they have been oxidized by neutralizing free radicals [1][2]. This regenerative capacity has led some researchers to call it the "universal antioxidant."
Managing Blood Sugar and Metabolic Health?
Alpha-lipoic acid may support insulin sensitivity, but metabolic health involves many factors. Get a personalized plan based on your health profile.
Get Your Personalized Health PlanThe body produces small amounts of alpha-lipoic acid endogenously, and it is obtained in trace amounts from dietary sources such as organ meats, spinach, broccoli, and yeast [1][2]. However, the amounts obtainable from diet (estimated at 1–2 mg/day from a typical mixed diet) are far below therapeutic dosages used in clinical studies (300–1,800 mg/day) [1][2]. Supplementation is therefore necessary to achieve pharmacological effects.
Alpha-lipoic acid exists in two mirror-image forms (enantiomers): the R-isomer and the S-isomer. The R-isomer is the naturally occurring form produced by the body and found in food. The S-isomer is produced synthetically and does not occur in nature. Most supplements contain a 50/50 racemic mixture of both isomers unless specifically labeled as R-alpha-lipoic acid or R-ALA [1][2]. The S-form is likely biologically inactive or neutral, although a patent exists on it as an analgesic [1]. The R-isomer is the biologically active form responsible for the antioxidant and metabolic effects observed in clinical studies.
Alpha-lipoic acid has been most extensively studied for diabetic peripheral neuropathy, where it has been approved as a prescription treatment in Germany since the 1960s [2]. It has also been investigated for blood sugar control, weight loss, liver disease, Alzheimer's disease, multiple sclerosis, and various pain conditions, with varying degrees of clinical support.
Forms and Bioavailability
Racemic (Mixed) Alpha-Lipoic Acid vs. R-Alpha-Lipoic Acid
Most alpha-lipoic acid supplements on the market contain a racemic (50/50) mixture of R- and S-isomers. This is the form used in the majority of clinical trials to date. The R-isomer is the naturally occurring, biologically active form. The S-isomer is likely inactive but may compete with the R-isomer for absorption [1][2].
Products specifically containing only the R-isomer are available but are significantly more expensive — typically five to seven times the cost per milligram compared to the racemic form [1]. Theoretically, a dose of R-isomer-only alpha-lipoic acid would be equivalent to approximately twice the amount of the racemic mixture, since only 50% of the racemic form is the active R-isomer [1].
Some animal studies suggest the R-isomer may be more effective than the S-isomer at improving insulin sensitivity, but head-to-head clinical studies in humans comparing the two forms have not been conducted [1].
Sodium R-Alpha-Lipoate (Na-RALA)
A stabilized sodium salt form of R-alpha-lipoic acid, known as sodium R-alpha-lipoate (Na-RALA), has been developed to address stability issues with pure R-lipoic acid (which can polymerize and degrade). A limited pharmacokinetic study in humans (funded by its manufacturer, GeroNova Research) showed that Na-RALA was more stable, more water-soluble, and achieved approximately 3 times higher blood levels of R-lipoic acid compared to a pure R-lipoic acid product — both taken after being dissolved in water and without food [3]. The FDA issued a warning letter to GeroNova Research in 2021 regarding efficacy claims made for this and other products [1].
Controlled-Release Formulations
Controlled-release (sustained-release or timed-release) formulations of alpha-lipoic acid are marketed as improving absorption and prolonging exposure. However, clinical research does not support this claim. A pharmacokinetic study among 12 healthy men (average age 61) who received a single 600 mg dose of either controlled-release or regular alpha-lipoic acid capsules found that the controlled-release formulation had only 59% of the bioavailability of regular capsules [4]. This means controlled-release formulations actually deliver less alpha-lipoic acid to the bloodstream, not more.
Effect of Food on Absorption
Taking alpha-lipoic acid with food reduces its bioavailability by approximately 25% [5]. For optimal absorption, alpha-lipoic acid should be taken at least 30 minutes before a meal or at least 2 hours after a meal, if tolerated [1][5]. However, taking it with food may reduce gastrointestinal side effects (particularly heartburn and nausea), which can be significant at higher doses [1].
Form Comparison Table
| Form | Active Component | Relative Bioavailability | Typical Cost | Notes |
|---|---|---|---|---|
| Racemic ALA (R/S mixture) | 50% R-isomer | Baseline | Lowest | Used in most clinical trials. Most widely available [1][2]. |
| R-Alpha-Lipoic Acid (R-ALA) | 100% R-isomer | Higher per mg | 5–7x racemic | Theoretically twice as potent per mg. Limited human comparison data [1]. |
| Na-RALA (sodium R-alpha-lipoate) | R-isomer (sodium salt) | ~3x higher peak levels than R-ALA | Highest | More stable and water-soluble. Limited human data, industry-funded [3]. |
| Controlled-release ALA | Varies | 59% of immediate-release | Moderate | Inferior bioavailability to standard capsules. Not recommended [4]. |
Evidence for Benefits
Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy — nerve damage causing burning, pain, numbness, and prickling in the feet and legs — is the most extensively studied indication for alpha-lipoic acid. This condition affects up to 50% of people with diabetes and can significantly impair quality of life.
Oral supplementation — short-term: A systematic review and meta-analysis of oral alpha-lipoic acid for diabetic neuropathy found that doses of 600 to 1,800 mg daily taken for 3 to 5 weeks modestly improved symptoms of peripheral neuropathy compared to placebo, reducing symptoms such as burning, pain, numbness, and prickling of the feet and legs, as well as improving sensation. However, the improvement was small and may not be clinically relevant — meaning it may not have a noticeable effect on daily life [6].
Comparison with pregabalin: A study in Canada among 44 people with nerve pain due to various conditions compared alpha-lipoic acid directly to pregabalin (Lyrica), a first-line prescription drug for neuropathic pain. After 6 weeks, alpha-lipoic acid reduced diabetic nerve pain intensity (on a 0–10 scale) from 5.32 at baseline to 3.53, while pregabalin reduced it to 2.72. Combining alpha-lipoic acid with pregabalin did not provide additional benefit beyond pregabalin alone. Alpha-lipoic acid was also less effective than pregabalin for nerve pain due to idiopathic small fiber neuropathy, chemotherapy-induced peripheral neuropathy, Charcot–Marie–Tooth disease, post-traumatic neuropathy, and post-herpetic neuralgia (shingles). In this study, alpha-lipoic acid was started at 300 mg daily and titrated up to 1,800 mg, while the average daily dose of pregabalin was 341 mg [7].
Cardiovascular benefits in diabetics: Beyond neuropathy symptoms, there is evidence that alpha-lipoic acid supplements may also help diabetic patients by lessening damage to the heart, kidneys, and small blood vessels associated with diabetes [1].
Blood Sugar Control and Insulin Sensitivity
Alpha-lipoic acid has been shown to improve insulin sensitivity and blood sugar control in people with type 2 diabetes across multiple studies.
Insulin sensitivity: Taking alpha-lipoic acid at doses of 300 to 1,200 mg daily appears to improve insulin sensitivity and blood sugar control in people with type 2 diabetes [1]. However, the effect on glycosylated hemoglobin (HbA1c) — the primary marker of long-term blood sugar control — may be only modest. A 6-month placebo-controlled study found only a slight reduction in HbA1c with alpha-lipoic acid supplementation [8].
Mechanism: Alpha-lipoic acid appears to enhance glucose uptake by activating AMP-activated protein kinase (AMPK), a master metabolic regulator, and by improving insulin receptor signaling. It also reduces oxidative stress, which is a key driver of insulin resistance in type 2 diabetes [2].
Weight Loss
Preliminary evidence suggests alpha-lipoic acid may aid weight loss by promoting the breakdown of fat (lipolysis) and inhibiting the formation of new fat cells (adipogenesis) [9][10]. Clinical studies show modest benefits when combined with a reduced-calorie diet, but alpha-lipoic acid does not appear to be as effective when taken without dietary changes.
In overweight/obese women on a reduced-calorie diet: A study of 77 healthy but sedentary overweight or obese women (ages 20–50) on a reduced-calorie diet found that those who took alpha-lipoic acid (300 mg per day as three 100 mg capsules with meals) or a combination of alpha-lipoic acid and the omega-3 fatty acid EPA (1,300 mg per day) for 10 weeks lost significantly more weight — an average of 15 lbs and 14 lbs, respectively — compared to those who took EPA only or placebo (average weight loss of 12 lbs and 11.5 lbs, respectively). The women who took alpha-lipoic acid alone or with EPA also lost significantly more body fat than those in the EPA-only or placebo groups [11].
In overweight adults with borderline-high triglycerides: A study of 55 overweight men and women with borderline-high triglycerides (averaging 178 mg/dL) who maintained their typical food intake and physical activity levels found that 600 mg of R-alpha-lipoic acid taken daily for 24 weeks modestly reduced BMI (body mass index) compared to placebo (a decrease of 6 kg/m² vs. an increase of 2 kg/m²). However, supplementation did not decrease body weight, fat mass, waist circumference, or triglyceride levels. Two capsules were taken on an empty stomach 30 minutes before breakfast. Side effects more common with alpha-lipoic acid than placebo included persistent heartburn and a strong odor in the urine [12].
Summary: Alpha-lipoic acid appears to modestly enhance weight and fat loss when combined with caloric restriction, but it is not effective as a standalone weight loss supplement without dietary changes. Larger and longer studies are needed to confirm these effects.
Liver Disease (MASLD/NAFLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD) — involves a buildup of fat in the liver that often occurs alongside metabolic disorders such as obesity and insulin resistance.
Primary study: A study in Iran among 45 obese people with MASLD found that alpha-lipoic acid (600 mg twice daily before meals) combined with vitamin E (400 IU) for 12 weeks did not improve body composition, most markers of liver injury, or hepatic steatosis compared to vitamin E with placebo. However, there was an increase in adiponectin levels (a hormone associated with weight loss and insulin sensitivity) and a decrease in insulin levels and leptin (a hormone linked with appetite) in the alpha-lipoic acid group [13][14].
Re-analysis of completers: A re-analysis of the same study data that excluded participants who discontinued treatment showed somewhat more encouraging results: 87.5% of those who received alpha-lipoic acid (versus 59.1% of placebo recipients) experienced a modest reduction in hepatic steatosis, and this difference was statistically significant. However, there was no difference in the percentage of participants who experienced larger reductions in steatosis, nor were there differences in reductions of other biomarkers of inflammation [15].
Summary: The evidence for alpha-lipoic acid in MASLD/NAFLD is limited and inconclusive. It does not appear to substantially improve liver injury markers, though it may have favorable effects on adiponectin and insulin levels.
Alzheimer's Disease and Cognitive Function
Combination with fish oil: A placebo-controlled, 1-year pilot study of 34 adults with mild to moderate impairment from Alzheimer's disease found that the combination of alpha-lipoic acid and fish oil slowed the decline in cognitive functioning compared to placebo. The combination also slowed the decline in subjects' ability to perform daily activities, as did fish oil alone, but alpha-lipoic acid alone did not slow functional decline. Participants normally ate fish no more than once per week, and most continued their Alzheimer's medications. The dosing was 600 mg of alpha-lipoic acid taken each morning along with 2 fish oil capsules at breakfast (each containing 1 g of fish oil providing 325 mg EPA and 225 mg DHA in the triglyceride form), with another fish oil capsule taken at lunch [16]. Although earlier studies had not shown a benefit with omega-3 fatty acids in Alzheimer's disease, this study differed in using fish oil with a high EPA-to-DHA ratio.
Limitations: This was a small pilot study (n=34) and the results have not been replicated in a larger trial. The relative contributions of alpha-lipoic acid versus fish oil versus the combination cannot be clearly separated.
Multiple Sclerosis
Animal model evidence: Alpha-lipoic acid reduced motor dysfunction in an animal model of multiple sclerosis (MS) [17].
Preliminary clinical evidence: An early clinical study suggested alpha-lipoic acid might reduce the progressive loss of brain tissue in people with MS [18].
Definitive negative trial: A subsequent well-designed 2-year study among 85 adults (average age 59) with progressive MS showed that taking 1,200 mg of alpha-lipoic acid with food once daily did not improve mobility, cognition, or quality of life, and did not reduce the frequency of falls, overall disability, fatigue, or pain compared to placebo. Moreover, a greater number of people in the alpha-lipoic acid group experienced nausea, protein in the urine, and poor kidney function than those given placebo [19].
Summary: Alpha-lipoic acid does not appear to be beneficial for progressive multiple sclerosis based on the most rigorous clinical trial available, and it was associated with more adverse effects including kidney-related concerns.
Pain Conditions (Non-Diabetic)
General nerve, muscle, and joint pain: A study in Italy among 210 men and women with mild to moderate nerve, muscle, or non-inflammatory joint pain without a known cause compared 400 mg of alpha-lipoic acid, 800 mg of alpha-lipoic acid, or placebo, taken once daily for two months. Both doses of alpha-lipoic acid moderately decreased self-reported pain compared to baseline, with somewhat better results at the higher dose, while there was no decrease in pain with placebo. Decreases in pain were similar regardless of pain type (nerve, muscle, or joint). There were no adverse effects on fasting blood sugar levels or measures of kidney and liver function [20].
Back pain with radiculopathy: In a study of adults being treated with physical therapy for back pain with radiating nerve pain, those who took 600 mg of alpha-lipoic acid and 360 mg of gamma-linolenic acid (GLA) daily for 6 weeks had a greater reduction in pain and improvement in function compared to those who did not take these supplements [21]. However, because this study used a combination therapy and lacked a placebo group, the specific benefit of alpha-lipoic acid for radiating nerve pain remains uncertain.
Chemotherapy-Induced Neuropathy
Negative trial: A clinical study among people receiving platinum-based chemotherapy found that taking 600 mg of alpha-lipoic acid three times daily (1,800 mg total) for 24 weeks during chemotherapy did not reduce the incidence of chemotherapy-related nerve damage compared to placebo. This study had a very high dropout rate, which limits the reliability of the results [22].
Professional recommendation: Based on this evidence, the American Society of Clinical Oncology (ASCO) recommends that clinicians NOT offer alpha-lipoic acid for the prevention of chemotherapy-induced peripheral neuropathy [23].
Hearing Loss
No benefit for age-related hearing loss: Alpha-lipoic acid does not appear to be beneficial for treating age-related hearing loss in humans, despite showing promise in animal models [24]. While a study by Seidman (2000) demonstrated potential for preventing age-related hearing loss in rats [25], this benefit has not been demonstrated in humans.
No benefit for noise-induced hearing loss: Taking a single 600 mg dose of alpha-lipoic acid one hour prior to noise exposure was not beneficial for preventing reversible noise-induced hearing loss in healthy young adults with normal hearing. A related study found that supplementing with 600 mg of alpha-lipoic acid for 10 days prior to noise exposure suggested some protection against changes in hearing measures compared to baseline, but the absence of a placebo group makes the results unreliable [26].
Burning Mouth Syndrome
While early research suggested alpha-lipoic acid might help treat burning mouth syndrome (BMS) — a condition characterized by unexplained scalding sensations in the mouth — a subsequent placebo-controlled study using 400 mg of alpha-lipoic acid for 8 weeks found no benefit compared to placebo [27].
Skin Aging
Alpha-lipoic acid has been promoted for improving the appearance of aging skin, but there is no clinical evidence that oral alpha-lipoic acid supplements have such an effect [1].
Topical application: A study testing a 5% alpha-lipoic acid cream (which also included small amounts of CoQ10 and acetyl-L-carnitine) applied daily to the faces of women age 40–75 for 12 weeks reported a 51% reduction in skin roughness. However, the same cream without alpha-lipoic acid (base cream alone) resulted in a 41% reduction, meaning the incremental benefit attributable to alpha-lipoic acid was only about 10 percentage points [28]. A longer study was noted to be in progress at the time, but results do not appear to have been published.
Other Potential Uses
The antioxidant effects of alpha-lipoic acid may provide theoretical protection in conditions including cerebral ischemia, mitochondrial dysfunction, aminoglycoside-induced cochlear damage, heavy metal and chemical poisoning, and radiation exposure [1][2]. Alpha-lipoic acid has also been shown to inhibit replication of HIV in vitro and, in AIDS patients, might improve blood antioxidant status and increase T-helper lymphocyte counts [1]. However, these applications remain theoretical or preliminary, without adequate clinical trial evidence in humans.
Recommended Dosing
Dosing by Indication
The following dosing recommendations are based on the racemic (mixed R/S isomer) form used in clinical trials. If using an R-isomer-only product, the dose may potentially be reduced by up to half, since the racemic form contains only 50% active R-isomer [1]. However, this has not been confirmed in comparative clinical trials.
| Indication | Dose (Racemic ALA) | Duration in Studies | Evidence Level |
|---|---|---|---|
| Diabetic peripheral neuropathy | 600–1,800 mg/day in divided doses | 3–5 weeks (oral) | Modest benefit, may not be clinically relevant [6][7] |
| Blood sugar control / insulin sensitivity | 300–1,200 mg/day | Up to 6 months | Improves insulin sensitivity; modest HbA1c effect [1][8] |
| Weight loss (with caloric restriction) | 300 mg/day (100 mg 3x with meals) | 10–24 weeks | Modest enhancement of weight/fat loss [11][12] |
| General pain (nerve, muscle, joint) | 400–800 mg/day | 2 months | Moderate pain reduction [20] |
| Alzheimer's disease (with fish oil) | 600 mg once daily | 12 months | Pilot data only (n=34) [16] |
| General antioxidant support | 20–50 mg/day | Not studied long-term | No clinical evidence of health benefit at this dose [1] |
Timing and Administration
Alpha-lipoic acid should ideally be taken on an empty stomach — at least 30 minutes before a meal or at least 2 hours after a meal — because food reduces bioavailability by approximately 25% [1][5]. If gastrointestinal side effects (heartburn, nausea) are problematic, taking it with food may improve tolerability at the cost of reduced absorption.
Higher daily doses (600 mg or more) should be divided into two or three doses rather than taken as a single dose [1].
Important Note on "General Antioxidant" Dosing
Although a dosage of 20–50 mg daily is commonly recommended for use as a general antioxidant, there is no evidence that taking alpha-lipoic acid at this dose provides any health benefit [1]. The clinical studies demonstrating benefits have used substantially higher doses (300–1,800 mg/day).
Storage
Store alpha-lipoic acid at room temperature away from moisture and heat. Consider refrigerating opened bottles, as heat and humidity can cause the powder in capsules to bind and become putty-like or hard, which could potentially reduce absorption in the digestive tract [1].
Safety and Side Effects
Common Side Effects
Gastrointestinal effects: Alpha-lipoic acid is an acid — slightly stronger than acetic acid (vinegar) — and has been known to cause heartburn and nausea, particularly at higher doses [12][29]. This may be especially problematic for people with acid reflux or stomach ulcers. Burning sensations from the throat to the stomach, and acid reflux, have been reported with high daily doses (800–1,800 mg). People taking stomach acid-blocking medications such as famotidine (Pepcid) or proton pump inhibitors such as esomeprazole (Nexium) may be less likely to experience these effects [30][31].
Theoretically, enteric-coated alpha-lipoic acid supplements may help prevent stomach irritation, but this has not been confirmed in clinical research [1]. Due to irritation to the throat, it is advisable not to take alpha-lipoic acid as a liquid, such as alpha-lipoic acid mixed in water [1].
Urine odor: Use of alpha-lipoic acid may cause a strong sulfurous odor in the urine due to its sulfur content [12].
Skin reactions: Skin rash and nausea have been reported with oral supplementation [29]. With topical use, rash and blistering have been reported with 5% alpha-lipoic acid creams, including a case in an 86-year-old woman who applied a 5% alpha-lipoic acid cream to her lower leg and thigh for chronic venous insufficiency [32], and cases of severe facial skin irritation from anti-aging creams containing 5% alpha-lipoic acid [33][34].
Serious Adverse Effects
Overdose toxicity: Extremely high doses of alpha-lipoic acid (6,000 mg or more in a single day) can result in overdose, causing nausea, drowsiness, mental confusion, seizures, shock, organ failure, and death. A case report described an 82-year-old woman in Denmark who had been taking 600 mg of alpha-lipoic acid daily for several years without side effects but developed nausea, vomiting, cold sweats, confusion, seizures, and coma three hours after accidentally ingesting 6,000 mg (6 grams). She required intensive care and mechanical ventilation but improved and was discharged three days after hospital admission [35].
Insulin autoimmune syndrome (IAS / Hirata disease): Although rare, alpha-lipoic acid supplementation has been reported to trigger insulin autoimmune syndrome in some individuals. A metabolite of alpha-lipoic acid may trigger autoantibodies against insulin, leading to high concentrations of total serum immunoreactive insulin and causing spontaneous episodes of fasting hypoglycemia (dangerously low blood sugar). Symptoms include sweating, shakiness, and weakness, typically occurring within 1 week to 4 months of starting supplementation at no specific dose [36].
A case report described a 79-year-old woman with type 2 diabetes controlled with metformin who experienced recurring episodes of fasting hypoglycemia one month after beginning alpha-lipoic acid supplementation. Blood tests confirmed autoantibodies against insulin suspected to be triggered by the supplement [36]. The condition is generally reversible with discontinuation of alpha-lipoic acid, but some patients have required pharmacologic treatment. People of Japanese, Korean, and Southern European ancestry may be genetically more predisposed to IAS [37].
Nutrient Interactions
Thiamin (vitamin B1) depletion: Very large doses of alpha-lipoic acid have caused serious toxicity in thiamin-deficient animals. People taking high doses of alpha-lipoic acid who are at risk for thiamin deficiency — such as those with chronic alcohol use — may require thiamin supplementation. Some diabetics may also be at risk for low thiamin levels [1].
Biotin (vitamin B7) reduction: Chronic use of alpha-lipoic acid may reduce some of the biological activities of biotin. This was demonstrated in a rat study, and co-administering biotin with alpha-lipoic acid eliminated this effect. However, the researchers noted that "even without supplemental biotin, the decreases in enzyme activities are not dramatic and would presumably not cause pathology in patients" [38].
Thyroid Effects
Alpha-lipoic acid appears to interfere with the conversion of T4 (thyroxine) to T3 (triiodothyronine), potentially lowering T3 levels. TSH (thyroid-stimulating hormone) may increase as a compensatory response [39]. Patients with thyroid disease — particularly those on levothyroxine replacement therapy — should be aware that alpha-lipoic acid may affect thyroid function and treatment efficacy.
Kidney Concerns at High Doses
In the 2-year MS trial using 1,200 mg/day, a greater number of participants in the alpha-lipoic acid group experienced protein in the urine (proteinuria) and poor kidney function compared to placebo [19]. This suggests that long-term high-dose supplementation may warrant monitoring of kidney function.
Drug Interactions
Anti-Diabetic Medications
Because alpha-lipoic acid may help control blood sugar in diabetics, it could potentially enhance the blood sugar-lowering effects of insulin and oral hypoglycemic agents (metformin, sulfonylureas, etc.), increasing the risk of hypoglycemia. Dosage adjustments to diabetes medications may be needed when starting or stopping alpha-lipoic acid [1].
Chemotherapy Agents
Although preliminary evidence suggested alpha-lipoic acid might counteract neuropathy from some chemotherapy drugs, there is a theoretical risk that antioxidants such as alpha-lipoic acid may decrease the effectiveness of chemotherapy. The American Society of Clinical Oncology recommends against using alpha-lipoic acid during chemotherapy [23]. Patients should discuss with their healthcare provider before using alpha-lipoic acid while receiving chemotherapy.
Thyroid Medications
Alpha-lipoic acid may interfere with thyroid hormone conversion (T4 to T3), potentially affecting the efficacy of levothyroxine and other thyroid medications [39]. Patients on thyroid medication should have thyroid function monitored if taking alpha-lipoic acid.
Mercury and Amalgam Fillings
Concern has been raised about the possibility of alpha-lipoic acid increasing exposure to mercury from amalgam dental fillings. This stems from an animal study showing that alpha-lipoic acid could cause mercury in rat kidneys to be redistributed to other organs including the brain, intestines, and muscle [40]. However, there does not appear to be evidence that alpha-lipoic acid affects tissue distribution of mercury in humans or that it causes mercury to leach from amalgam fillings [1].
Dietary Sources
The body produces small amounts of alpha-lipoic acid endogenously, and it can be obtained from food. However, dietary intake is estimated at only 1–2 mg per day from a typical mixed diet — far below the therapeutic doses used in clinical studies (300–1,800 mg/day) [1][2].
Food Sources of Alpha-Lipoic Acid
| Food | Alpha-Lipoic Acid Content | Notes |
|---|---|---|
| Kidney (organ meat) | Highest food source | Richest dietary source of ALA [1][2] |
| Heart (organ meat) | High | Mitochondria-rich organ meat [1][2] |
| Liver (organ meat) | High | Rich in mitochondria [1][2] |
| Spinach | Moderate | Best plant source [1][2] |
| Broccoli | Moderate | Common vegetable source [1][2] |
| Tomatoes | Low–Moderate | Minor contributor [2] |
| Peas | Low–Moderate | Minor contributor [2] |
| Brussels sprouts | Low–Moderate | Minor contributor [2] |
| Brewer's yeast | Moderate | Concentrated source [1] |
| Rice bran | Low | Minor contributor [2] |
Practical Notes
- The alpha-lipoic acid in food is bound to proteins (specifically to lysine residues in enzymes) and is released during digestion [2]. The bioavailability of food-derived ALA versus supplemental free ALA has not been directly compared.
- Even the richest dietary sources provide only microgram quantities, which are insufficient for any therapeutic effect. A serving of spinach, for example, provides far less than 1 mg of alpha-lipoic acid.
- A healthy body produces enough alpha-lipoic acid endogenously to supply its requirements as an enzyme cofactor. Supplementation is only necessary for pharmacological (therapeutic) dosing above physiological levels [1].
Managing Blood Sugar and Metabolic Health?
Alpha-lipoic acid may support insulin sensitivity, but metabolic health involves many factors. Get a personalized plan based on your health profile.
Get Your Personalized Health PlanReferences
1. ConsumerLab. "Alpha-Lipoic Acid Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/alpha-lipoic-acid-supplements/alphalipoic/
2. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. "Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential." Biochim Biophys Acta. 2009;1790(10):1149-1160. https://doi.org/10.1016/j.bbagen.2009.07.026
3. Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L. "The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects." Altern Med Rev. 2007;12(4):343-351. https://pubmed.ncbi.nlm.nih.gov/18069903/
4. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. "Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid." Endocr Pract. 2002;8(1):29-35. https://pubmed.ncbi.nlm.nih.gov/11939038/
5. Gleiter CH, Schreeb KH, Freudenthaler S, et al. "Lack of interaction between thioctic acid, glibenclamide and acarbose." Eur J Clin Pharmacol. 1996;50(6):513-514. https://pubmed.ncbi.nlm.nih.gov/8858280/
6. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. "Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials." Int J Endocrinol. 2012;2012:456279. https://doi.org/10.1155/2012/456279
7. Gilron I, et al. "Alpha-lipoic acid versus pregabalin for neuropathic pain." Pain. 2024. https://doi.org/10.1097/j.pain.0000000000003166
8. Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A. "Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study." Asia Pac J Clin Nutr. 2012;21(1):12-21. https://pubmed.ncbi.nlm.nih.gov/22374556/
9. Fernandez-Galilea M, Perez-Matute P, Prieto-Hontoria PL, et al. "Alpha-lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects." J Lipid Res. 2012. https://pubmed.ncbi.nlm.nih.gov/22670071/
10. Carrier B, Rideout TC. "Anti-obesity and lipid-lowering properties of alpha-lipoic acid." J Human Nutr Food Sci. 2013;1(1):1003.
11. Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martinez JA, Moreno-Aliaga MJ. "Effects of alpha-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss." Obesity. 2015;23(2):313-321. https://doi.org/10.1002/oby.20966
12. Bobe G, Zhang Z, Kopp R, et al. "Bioavailability of Alpha-Lipoic Acid and Its Effect on Body Weight and Body Composition in Overweight/Obese Adults with Borderline-High Triglycerides." J Nutr. 2020;150(12):3141-3148. https://doi.org/10.1093/jn/nxaa273
13. Hosseinpour-Arjmand S, Amirkhizi F, Ebrahimi-Mameghani M. "The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease." J Clin Pharm Ther. 2019;44(2):258-267. https://pubmed.ncbi.nlm.nih.gov/30597614/
14. Rahmanabadi A, Mahboob S, Amirkhizi F, Hosseinpour-Arjmand S, Ebrahimi-Mameghani M. "Oral alpha-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features." Food Funct. 2019;10(8):4941-4952. https://pubmed.ncbi.nlm.nih.gov/31334738/
15. Ebrahimi-Mameghani M, et al. "Alpha-lipoic acid and hepatic steatosis: a re-analysis." J Funct Foods. 2024.
16. Shinto L, Quinn J, Montine T, et al. "A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease." J Alzheimers Dis. 2014;38(1):111-120. https://doi.org/10.3233/JAD-130722
17. Marracci GH, Jones RE, McKeon GP, Bourdette DN. "Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis." J Neuroimmunol. 2002;131(1-2):104-114. https://pubmed.ncbi.nlm.nih.gov/12458042/
18. Spain R, Powers K, Murchison C, et al. "Lipoic acid in secondary progressive MS: A randomized controlled pilot trial." Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e374. https://doi.org/10.1212/NXI.0000000000000374
19. Spain R, et al. "Lipoic acid for progressive multiple sclerosis: a 2-year randomized controlled trial." Neurology. 2026.
20. Esposito C, Garzarella EU, Santarcangelo C, et al. "Efficacy of alpha-lipoic acid supplementation for management of mild to moderate pain." Biomed Pharmacother. 2021;139:111607. https://doi.org/10.1016/j.biopha.2021.111607
21. Ranieri M, Sciuscio M, Cortese AM, et al. "The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain." Int J Immunopathol Pharmacol. 2009;22(3 Suppl):45-50. https://pubmed.ncbi.nlm.nih.gov/19887044/
22. Guo Y, Jones D, Palmer JL, et al. "Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial." Support Care Cancer. 2014;22(5):1223-1231. https://doi.org/10.1007/s00520-013-2075-1
23. Loprinzi CL, Lacchetti C, Bleeker J, et al. "Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update." J Clin Oncol. 2020;38(28):3325-3348. https://doi.org/10.1200/JCO.20.01399
24. Polanski JF, Cruz OL. "Evaluation of antioxidant treatment in presbyacusis." J Laryngol Otol. 2013;127(2):134-141. https://doi.org/10.1017/S0022215112003118
25. Seidman MD. "Effects of dietary restriction and antioxidants on presbyacusis." Am J Otol. 2000;21(4):580-586. https://pubmed.ncbi.nlm.nih.gov/10901571/
26. Quaranta A, Scaringi A, Bartoli R, Margarito MA, Quaranta N. "The effects of 'supra-physiological' vitamin B12 administration on temporary threshold shift." Acta Otorhinolaryngol Ital. 2012;32(6):382-388. https://pubmed.ncbi.nlm.nih.gov/23349558/
27. Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S. "Lack of efficacy of alpha-lipoic acid in burning mouth syndrome." Eur J Pain. 2009;13(5):492-496. https://doi.org/10.1016/j.ejpain.2008.06.004
28. Beitner H. "Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% alpha-lipoic acid related to photoageing of facial skin." Br J Dermatol. 2003;149(4):841-849. https://doi.org/10.1046/j.1365-2133.2003.05597.x
29. Derosa G, D'Angelo A, Romano D, Maffioli P. Drug Des Devel Ther. 2020;14:2295-2305. https://doi.org/10.2147/DDDT.S246970
30. Gu XQ, et al. "Alpha-lipoic acid for diabetic peripheral neuropathy." Zhonghua Yi Xue Za Zhi. 2010.
31. Sarezky D, Raquib AR, Engell JC, et al. "Tolerability in the elderly population of high-dose alpha lipoic acid." Clin Ophthalmol. 2016;10:1899-1903. https://doi.org/10.2147/OPTH.S115900
32. Corazza M, et al. "Allergic contact dermatitis from alpha-lipoic acid cream." Contact Dermatitis. 2023.
33. Leysen J, et al. "Allergic contact dermatitis from alpha-lipoic acid in anti-aging creams." Contact Dermatitis. 2016.
34. Bergqvist-Karlsson A. "Contact dermatitis to alpha-lipoic acid in anti-wrinkle cream." Contact Dermatitis. 2006.
35. Heerfordt IM, et al. "Alpha-lipoic acid overdose: a case report." Clin Nutr ESPEN. 2026.
36. Kitsios K, et al. "Alpha-lipoic acid-induced insulin autoimmune syndrome." Ann Intern Med Clin Cases. 2024.
37. Turck D, et al. "Safety of alpha-lipoic acid as a novel food." EFSA Journal. 2021. https://doi.org/10.2903/j.efsa.2021.6580
38. Zempleni J, Trusty TA, Mock DM. "Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver." J Nutr. 1997;127(9):1776-1781. https://pubmed.ncbi.nlm.nih.gov/9278559/
39. Segermann J, Hotze A, Ulrich H, Rao GS. "Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine." Arzneimittelforschung. 1991;41(12):1294-1298. https://pubmed.ncbi.nlm.nih.gov/1812469/
40. Patrick L. "Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity." Altern Med Rev. 2002;7(6):456-471. https://pubmed.ncbi.nlm.nih.gov/12495372/
